Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients

Clinical Cancer Research

Volumn 11, Issue 4, 2005, Pages 1534-1538

  Suk, Rebecca ^a   Gurubhagavatula, Sarada ^a   Park, Sohee ^a   Zhou, Wei ^a   Su, Li ^a   Lynch, Thomas J ^a   Wain, John C ^a   Neuberg, Donna ^a   Liu, Geoffrey ^a   Christiani, David C ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PLATINUM DERIVATIVE;

ADULT; AGED; ALLELE; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CODON; CONFIDENCE INTERVAL; DISEASE SEVERITY; ESOPHAGITIS; EVALUATION; EXCISION REPAIR; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PERFORMANCE; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTOPENIA; UNITED STATES; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; DRUG THERAPY; ENDONUCLEASES; FEMALE; GENE FREQUENCY; GENOTYPE; HEMATOLOGIC DISEASES; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX; VOMITING;

EID: 20044368468     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1953     Document Type: Article

References (30)

1. Mountain C. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
3. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
4. Liu G, Miller DP, Zhou W, et al. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histologic subtype of NSCLC. Cancer Res 2001;61:8718-22.
5. Zhou W, Liu G, Thurston SW, et al. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. Cancer Epidemiol Biomarkers Prev 2002;11:15-21.
6. Park, JY, Lee SY, Jeon HS, et al. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2002;11:23-7.
7. Cardenal F, Ramirez JL, Astudillo J, et al. XPD and RRM1 gene polymorphisms predict gemcitabine/cisplatin/docetaxel outcome in stage III NSCLC: a genetic analysis of the Spanish Lung Cancer Group phase II trial 9901. Proc ASCO 2003;22:649.
8. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-601.
9. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001;1:22-33.
10. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513-30.
11. Enzlin JH, Scharer OD. The active site of the DNA repair endonuclease XPF-ERCC1 forms a highly conserved nuclease motif. EMBO J 2002;21:2045-53.
12. Bessho T, Sancar A, Thompson LH, Thelen MP. Reconstitution of human excision nuclease with recombinant XPF-ERCC1 complex. J Biol Bhem 1997;272:3833-7.
13. Sturgis EM, Dahlstrom KR, Spitz MR, Wei Q. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2002;128:1084-8.
14. Chen P, Wiencke J, Aldape K, et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 2000;9:843-7.
15. Cheng L, Spitz MR, Hong WK, Wei Q. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case control analysis. Carcinogenesis 2000;21:1527-30.
16. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells. Biochem Pharmacol 2000;60:1305-13.
17. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. JCI 1994;94:703-8.
18. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 2000;89:453-7.
19. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-16.
20. Park DJ, Zhang W, Stoehlmacher J, et al. ERCC1 gene polymorphism as a predictor of clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clinical Advances in Hematology and Oncology 2003;1:162-6.
21. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotheapy. J Clin Oncol 2001;19:4298-304.
22. Lord RVN, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.
23. Yu JJ, Mu C, Lee KB, et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res 1997;382:13-20.
24. Shen MR, Jonse IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998;58:604-8.
25. Zhou W, Liu G, Thurston SW, et al. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer. Cancer Epidemiol Biomarkers Prev 2002;11:15-21.
26. Wei Q, Cheng L, Hong WK, Spitz MR. Reduced DNA repair capacity in lung cancer patients. Cancer Res 1996;56:4103-7.
27. Wei Q, Cheng L, Amos C, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000;92:1764-72.
28. Moore-Joshi MH, Danenberg KD, Lord RV, et al. Low thymidylate synthase and ERCC1 gene expressions are associated with increased survival after neoadjuvant 5FU/cisplatin/radiotherapy for esophageal adenocarcinoma. Proc ASCO 2000;18:244A.
29. Metzger R, Schneider PM, Baldus SE, et al. Quantitative ERCC1 RNA expression identifies non-response in cis-platinum based neo-adjuvant radiochemotherapy for esophageal cancer. Proc ASCO 2001;20:130a.
30. Grunberg SM, Hesketh P. Drug therapy: control of chemotherapy induced emesis. N Engl J Med 1993;329:1790.